Innovent Biologics has dosed the first subject in a first-in-human Phase I trial of IBI3002 to treat asthma.

The double-blind, randomised, placebo-controlled, single ascending dose (SAD) trial has begun dosing participants in Australia.

It is designed to assess the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IBI3002 in both healthy individuals as well as those with mild to moderate asthma.

IBI3002 is an interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP) directed bispecific antibody.

IL-4Rα and TSLP are both implicated in the pathophysiology of type 2 (T2) inflammatory disorders.

The antibody’s mechanism involves the dual-blocking of IL-4Rα and TSLP, which are central to cytokine signalling pathways in T2 inflammation, a common feature in asthma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In-vitro assays have indicated that IBI3002 may have superior efficacy compared to existing monoclonal antibodies targeting the same molecules.

The potential of IBI3002 to suppress both T2 and non-T2 inflammation could represent a significant advancement in the treatment of inflammatory ailments.

Innovent Clinical Development vice-president Dr Lei Qian said: “In the last few decades, knowledge about both pathophysiological mechanisms, clinical phenotypes and therapeutic options for asthma have significantly increased.

“In particular, the introduction of biologics for severe asthma paved the way to a true revolution in the field of asthma management, by potentially allowing a precision medicine approach.

“Targeting specific steps of the immune-inflammatory cascade through highly selective drugs represents a true revolution in the field of severe asthma management, and brings with it the potential of achieving optimal disease control in different severe asthma inflammatory phenotypes.”

Last month, Innovent reported positive results from its Phase III RESTORE-1 clinical trial of IBI311 in Chinese patients with thyroid eye disease (TED), meeting the primary endpoint.

The RESTORE-1 trial was a randomised, multicentre, placebo-controlled double-masked study evaluating the safety and efficacy of IBI311 for TED.